Venture&Growth Archives - Page 33 of 60 - Gilde Healthcare

Menu
Menu
Home

News

News

News
Venture&Growth

News
Private Equity

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...

9 July 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...

9 July 2025

Gilde Healthcare’s Private Equity-Fonds kombiniert Artinis und NIRx zu einer weltweit führenden Neuroimaging-Gruppe

Gilde Healthcare gibt heute eine kombinierte Private-Equity-Investition in Artinis Medical Systems (Niederlande) und NIRx Medical Technologies (Deutschland/Vereinigte Staaten) bekannt. Beide Unternehmen sind Pioniere auf dem Gebiet der funktionellen Nahinfrarot-Spektroskopie (fNIRS)....

8 July 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug...

9 July 2025

Filter & Suche

Fondsstrategie :
  • Alle
  • Private Equity
  • Venture&Growth
Suche:

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for pr...

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary...
9. Juli 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Sta...

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007 in Stargardt disease   Funding will also advance a broader pipeline of genetic...
11. Juni 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance ...

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases. Gilde Healthcare joined the...
3. Juni 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by An...

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8 is the only therapy considered medically necessary by the policy when the...
28. April 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Applicati...

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activity Phase 1 clinical trial of TGW101 initiated; Company plans...
22. April 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke has been appointed as new chair of the board of directors, reflecting...
1. April 2025

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study ...

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused...
13. März 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivi...

MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor, together with Longitude Capital. Existing investors include US Venture Partners (USVP), Osage...
12. März 2025

Gilde Healthcare Company Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive ...

Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors effective immediately. Haseeb has been appointed to steer Purespring through a critical phase of development...
12. März 2025
Loading...
Das waren alles Artikel
9e1dcc2192